Serum CRP levels in pre-dialysis patients

Renal Failure

Volumn 30, Issue 2, 2008, Pages 193-198

  Razeghi, Effat ^a   Parkhideh, Sayeh ^a   Ahmadi, Farrokhlagha ^a   Khashayar, Patricia ^a,b  

^a UNIVERSITY OF TEHRAN   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

C reactive protein; Dialysis; GFR; Serum albumin

Indexed keywords

ALBUMIN; BETA INTERFERON; C REACTIVE PROTEIN; CHOLESTEROL; FERRITIN; FIBRINOGEN; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; TRANSFERRIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CORRELATION FUNCTION; CREATININE BLOOD LEVEL; DEMOGRAPHY; DIALYSIS; FEMALE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN DETERMINATION; HUMAN; INFLAMMATION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NUTRITION; OUTPATIENT; PREVALENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS;

ADULT; AGED; C-REACTIVE PROTEIN; CREATININE; CROSS-SECTIONAL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INFLAMMATION MEDIATORS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; RENAL DIALYSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 39749189999     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220701810539     Document Type: Article

References (29)

1. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: Sources, consequences, and therapy. Semin Dial. 2002;15(5):329-337.
2. Nube M. The acute phase response in chronic hemodialysis patients: A marker of cardiovascular disease? Nephrol Dial Transplant. 2002;17:19-23.
3. Rattazzi M, et al. New markers of accelerated atherosclerosis in end stage renal disease. J Nephrol. 2003;16:11-20.
4. Kaysen GA, Eiserich JP. Characteristics and effects of inflammation in end-stage renal disease. Semin Dial. 2003;16(6):438-446.
5. Verhave JC, et al. The association between atherosclerotic risk factors and renal function in the general population. Kidney Int. 2005;67:1967-1973.
6. Park JS, Kim SB. C-reactive protein as a cardiovascular risk factor and its therapeutic implications in end-stage renal disease patients. Nephrology. 2003;8:S40-S44.
7. Vidt DG. Inflammation in renal disease. Am J Cardiol. 2006;97(2A):20A-27A.
8. Wanner C, Metzger T.C-reactive protein a marker for allcause and cardiovascular mortality in hemodialysis patients. Nephrol Dial Transplant. 2002;17:29-32.
9. Lacson Jr E, Levin NW. C-reactive protein and end-stage renal disease. Semin Dial. 2004;17(6):438-448.
10. Lacson Jr E, et al. What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients? Semin Dial. 2000;13(3):164-166.
11. Busch M, et al. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney Int. 2004;66:338-347.
12. Stenvinkel P. Inflammation in end-stage renal disease: The hidden enemy. Nephrology. 2006;11:36-41.
13. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Fermo I, Foca A, Paroni R, Malatino LS. Inflammation is associated with carotid atherosclerosis in dialysis patients. J Hypertens. 2000;18:1207-1213.
14. Panichi V, Migliori M, De Pietro S, Taccola D, Bianchi AM, Norpoth M, Metelli MR, Giovannini L, Tetta C, Palla R.C reactive protein in patients with chronic renal diseases. Ren Fail. 2001;23(3-4):551-562.
15. Stenvinkel P, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55:1899-1911.
16. Ortega O, Gallar P, Munoz M, Rodriguez I, Carreno A, Ortiz M, Molina A, Oliet A, Lozano L, Vigil A. Significance of high C-reactive protein levels in pre-dialysis patients. Nephron Dial Transplant. 2002;17:1105-1109.
17. Nascimento MM, Pecoits-Filho R, Lindholm B, Riella MC, Stenvinkel P. Inflammation, malnutrition and atherosclerosis in end stage renal disease: A global perspective. Blood Purif. 2002;20:454-458.
18. Wong JS, Port FK, Hulbert-Shearon TE, et al. Survival advantage in Asian American end-stage renal disease patients. Kidney Int. 1999;55:2515-2523.
19. Stenvinkel P, Lindholm B, Heimbürger O. Novel approaches in an integrated therapy of inflammatory-associated wasting in end stage renal disease. Semin Dial. 2004;17:505-515.
20. Ates K, Yilmaz O, Kutlay S, Ates A, Nergizoglu G, Erturk S. Serum C-reactive protein level is associated with renal function and it affects echocardiographic cardiovascular disease in predialysis patients. Nephron Clin Pract. 2005;101(4):c190-c197.
21. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999; 340:448-454.
22. Pecoits-Filho R, Heimbürger O, Barany P, Suliman M, Fehrman-Ekholm I, Lindholm B, Stenvinkel P. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis. 2003;41:1212-1218.
23. Stenvinkel P, Andersson A, Wang T, Lindholm B, Bergström J, Palmblad J, Heimbürger O, Cederholm T. Do ACE-inhibitors suppress tumor necrosis factor-α production in advanced chronic renal failure? J Intern Med. 1999; 246:503-507.
24. Ridker PM, Cushman M, Stampfer MJ, Russell PT, Hennekens CH. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1999;336:973-979.
25. Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB. Effects of simulation on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis. 2002;39:1213-1217.
26. Devaraj S, Jialal I. Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type-2 diabetic patients. Free Radic Biol Med. 2000;29:790-792.
27. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial. Lancet. 2000;356:1213-1218.
28. Locatelli F, Cante F, Marcelli D. The impact of haematocrit levels and erythropoetin treatment on overall and cardiovascular mortality and morbidity: The experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant. 1998;13:1642-1644.
29. Stenvinkel P, Barany P. Anaemia, rHuEPO resistance, and cardiovascular disease in end stage renal failure: Links to inflammation and oxidative stress. Nephrol Dial Transplant. 2002;17(Suppl. 5):32-37.